Drug Profile
GC 3111A
Alternative Names: GC-3111; GC3111ALatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Green Cross
- Developer GC Biopharma
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diphtheria; Pertussis; Tetanus
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 28 Sep 2021 GC 3111A is still in phase II trials for Diphtheria, Pertussis and Tetanus (Prevention) in South Africa (GC Pharma pipeline, September 2021)
- 14 Oct 2019 Green Cross Corporation initiates enrolment in a phase II trial for Diphtheria, Pertussis and Tetanus (Prevention) in South Korea (IM) (NCT04238975)